Benjamin J. Lee

General Surgery

1356 Lusitana St Fl 6
Honolulu, HI 96813

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

Journal: Leukemia & lymphoma

Published: August 20, 2026

Circulating Biomarkers in Cardio-Oncology: Prediction and Prognostication.

Circulating Biomarkers in Cardio-Oncology: Prediction and Prognostication.

Journal: Current cardiology reports

Published: June 16, 2026

Real-world evidence for the impact of circadian clock on the benefit from immune checkpoint inhibitors in solid tumors.

Real-world evidence for the impact of circadian clock on the benefit from immune checkpoint inhibitors in solid tumors.

Journal: BMC cancer

Published: May 08, 2026

Rapid HHV-6 Clearance Following Preemptive Short-Course Foscarnet in Allogeneic Stem Cell Transplant Recipients.

Rapid HHV-6 Clearance Following Preemptive Short-Course Foscarnet in Allogeneic Stem Cell Transplant Recipients.

Journal: American journal of hematology

Published: February 15, 2026

A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: The Liberation From Acute Dialysis (LIBERATE-D) Randomized Clinical Trial.

A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: The Liberation From Acute Dialysis (LIBERATE-D) Randomized Clinical Trial.

Journal: JAMA

Published: November 07, 2025

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.

Journal: British journal of haematology

Published: August 28, 2025

Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation.

Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation.

Journal: EJHaem

Published: June 26, 2025

The Kidney Disease Screening and Awareness Program: Transforming Community Outreach and Inspiring Interest in Nephrology.

The Kidney Disease Screening and Awareness Program: Transforming Community Outreach and Inspiring Interest in Nephrology.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: May 21, 2025

R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma.

R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 06, 2025

Thrombotic microangiopathy multidisciplinary assessment team: demographics, final diagnosis, treatment, and outcomes.

Thrombotic microangiopathy multidisciplinary assessment team: demographics, final diagnosis, treatment, and outcomes.

Journal: BMC nephrology

Published: April 24, 2025

Vitamin D deficiency in prostate cancer: Prevalence in a sun-rich climate and influence of androgen deprivation therapy.

Vitamin D deficiency in prostate cancer: Prevalence in a sun-rich climate and influence of androgen deprivation therapy.

Journal: World journal of clinical oncology

Published: April 07, 2025

Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT).

Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT).

Journal: Bone marrow transplantation

Published: January 17, 2025

Showing 1-12 of 67

Last Updated: 09/26/2026